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ABSTRACT 
Elevated level of plasma homocysteine (Hcy) has been identified as an independent risk factor 
for coronary artery disease (CAD). Furthermore, numerous studies have documented the in-
fluences of a common polymorphism (C677T) of methylenetetrahydrofolate reductase 
(MTHFR) on homocysteine levels. However the relationship between this mutation and car-
diovascular diseases (CVD) has remained as a controversial issue. The present study was un-
dertaken to investigate the relationship between C677T polymorphism of MTHFR gene, 
plasma total Hcy levels and the number of affected vessels as a criterion for the extent of 
CAD. MTHFR genotypes and plasma homocysteine (HCY) concentrations were examined in 
231 patients and 300 healthy subjects who underwent diagnostic coronary angiography. A 
multiple linear regression analysis was performed to identify the predictors of Hcy levels 
whereas logistic regression model was built to determine the association of Hcy quartiles with 
the risk of CAD adjusted for risk factors. The prevalence of MTHFR genotypes was similar 
between CAD patients and non-CAD individuals while the geometric mean of Hcy values 
was significantly higher in patient group (14.13 ± 4.11 μmol/l) than in control group (10.19 ± 
3.52 μmol/l) (P < 0.001). Moreover, unlike the MTHFR polymorphism, Hcy concentration in-
creased with increasing number of stenosed vessels and the CAD risk increased about 2 folds 
in the top two Hcy quartiles (≥ 17.03 and 13.20-17.02 μmol/l) compared with the lowest quar-
tile (≤ 9.92 μmol/l) after controlling for conventional risk factors (P<0.001 for both). Our data 
suggest that hyperhomocysteinaemia (HHcy) is significantly associated to CAD risk increase 
as well as to the extent of coronary atherosclerosis. 
 
Keywords: Methylene tetrahydrofolate reductase, homocystein, coronary artery disease,  
vessel score 
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INTRODUCTION 
Higher plasma homocysteine (Hcy) 
concentrations are considered as an inde-
pendent risk factor for coronary artery dis-
ease (CAD) (reviewed in De Bree et al., 
2002; Ford et al., 2002; Parnetti et al., 
2002). Hyperhomocysteinaemia (HHcy) in-
duced atherosclerosis is characterized by 
endothelial oxidative damage and dysfunc-
tion followed by platelet activation, promo-
tion of platelet aggregation, alteration of the 
normal procoagulant-anticoagulant balance 
and thrombosis (Durand et al., 1997; Hajjar 
et al., 1998; Visioli et al., 2002). Elevations 
of plasma Hcy has been associated with ge-
netic defects in enzymes involved in its me-
tabolism and/or with nutritional deficien-
cies of vitamin B6, B12, and folic acid 
(Brouwer et al., 1999; Kullo et al., 2006). 
The 5,10-methylene tetrahydrofolate re-
ductase (MTHFR) catalyzes the reduction 
of 5,10-methylene tetrahydrofolate to 5-
methyltetrahydrofolate. The latter is the 
methyl donor in the conversion reaction of 
Hcy to methionine which is catalyzed by 
the vitamin B12-dependent methionine syn-
thase. MTHFR-encoding gene has been re-
ported to be a genetic determinant of HHcy 
(Franken et al., 1996). A common substitu-
tion in this gene produces a thermolabile 
variant of MTHFR with specific decreased 
enzymatic activity which in turn leads to 
higher total Hcy (tHcy) concentrations in 
plasma (Frosst et al., 1995). The molecular 
basis of this thermolability is a substitution 
of a cytosine to thymine at nucleotide 677 
(rs1801133) in exon 4 of the MTHFR gene 
that converts an alanine to a valine codon 
(Frosst et al., 1995). 
Since the coronary atherosclerotic dis-
ease is the leading cause of death and disa-
bility among Iranian population (Hatmi et 
al., 2007), the present study sought to in-
vestigate whether there is an association be-
tween C667T polymorphism of MTHFR 
gene and plasma Hcy levels, as well as to 
evaluate the relationship of this polymor-
phism and the tHcy concentrations with the 
extension of the coronary artery disease.  
MATERIALS AND METHODS 
Study subjects 
The study population comprised 300 
healthy controls and 231 patients with 
premature CAD. All subjects in this study 
were recruited at three major university 
hospitals (Saadi, Kowsar and Nemazee) in 
Shiraz between July 2010 and March 2012. 
Women and men enrolled in the current in-
vestigation were all under 55 and 50 years 
of age respectively. All study participants 
were informed about the study’s objectives, 
and an informed consent was obtained from 
those who agreed to participate. The Hu-
man Ethics Committee at the Medical Uni-
versity of Shiraz, Iran, approved the study 
protocol. At the time of subject enrollment, 
information about the standard risk factors 
of CAD and relevant data on past medical 
history such as diabetes mellitus, hyperten-
sion, smoking habits, family history and 
drug therapy was collected from all indi-
viduals. Diabetics were recognized as those 
with FBS levels higher than 126 mg/dl or 
subjects who were using oral hypoglycemic 
agents or insulin. Liver dysfunction, renal 
failure, chronic or acute infectious disease, 
pernicious anemia, hypothyroidism, use of 
anti-inflammatory drugs, steroids and vita-
mins supplementation (which might influ-
ence homocysteine levels) were accepted as 
exclusion criteria. The data of hypertension, 
smoking habits, diabetes mellitus, and fami-
ly history of heart disease (defined as the 
incidence of myocardial infarction (MI), 
coronary artery disease and coronary artery 
bypass graft (CABG) in at least one of their 
first or second degree relatives) were regis-
tered as a two level variable. Smoking sta-
tus was coded as ever and never smokers. 
All of the subjects were of Iranian an-
cestry and none were first- or second-
degree relatives. 
 
Premature coronary artery disease 
All participants underwent coronary an-
giography on account of premature CAD as 
a verified illness or presumptive diagnosis. 
Coronary angiography was carried out by 
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the Judkins technique, with images record-
ed on compact disks. Subjects with more 
than 50 % stenosis in one or more of their 
three major coronary arteries (left anterior 
descending (LAD), left circumflex (LCx), 
and right coronary artery (RCA)) or their 
primary branches were considered as pa-
tients. All vessels were assessed from mul-
tiple angles by two experienced interven-
tional cardiologists blinded to the patients' 
MTHFR genotype and tHcy concentration. 
Based on the number of involved coronary 
arteries (0-3), participants were sub-
classified as follows: No vessel disease 
(NVD) who had no significantly stenosed 
vessels (< 50 % luminal stenosis); single 
vessel disease (SVD), who had one signifi-
cantly stenosed vessel; double vessel dis-
ease (DVD), who had two significantly ste-
nosed vessels; and triple vessel disease 
(TVD), who had severe CAD involving all 
the three major arteries. 
 
Biochemical analysis 
10 mL of venous blood samples (5 mL 
in EDTA and 5 mL without anticoagulant) 
were collected from each subject after 
overnight fasting. Blood samples without 
anticoagulant were freshly used for measur-
ing the participants' lipid and sugar profiles 
by standard enzymatic assays (Pars 
Azmoon, diagnostic kits, Iran). EDTA con-
taining portions which had been kept on ice 
in the dark were centrifuged within 90 min 
at 2500 rpm for 10 min at 4 oC. Resulted 
plasma fractions were aliquoted and stored 
at -70 oC until Hcy and folate estimation. 
High performance liquid chromatography 
(HPLC) with a fluorescent detector was 
used for determining the tHcy levels ac-
cording to Araki and Sako (1987) whereas 
the plasma concentrations of folate were 
obtained by an automated chemilumines-
cence method (Rozen, 1997). HHcy was 
defined as a plasma tHcy level ≥15 μmol/L. 
 
Genotype determination 
Genomic DNA was extracted from pe-
ripheral blood leukocytes using salting out 
method (Miller et al., 1988). Detection of 
the C677T polymorphism in the MTHFR 
gene was performed by PCR-RFLP analysis 
according to protocol conditions and primer 
sequences reported previously (Frosst et al., 
1995). Briefly, a 198 bp fragment surround-
ing the supposed mutation site was obtained 
by the following primers:  
forward:  
5'-TGAAGGAGAAGGTGTCTGCGGGA-3'; 
reverse:  
5'-AGGCGGTGCGGTGAGAGTG-3'.  
The PCR mixture (20 ml) contained 
50 ng of genomic DNA, 10 pmol of each 
primer, 1.5 mM MgCl2, 2.5 mM of each 
dNTP, 1X PCR buffer and 1 U of Taq poly-
merase (Fermentas). The cycle parameters 
were 3 min initial denaturation at 94 °C, 
followed by 35 subsequent cycles of ampli-
fication at 94 °C for 45 sec, at 65 °C for 
45 sec, and 72 °C for 45 sec. Final exten-
sion step was performed at 72 °C for 7 min. 
The PCR products were then subjected to 
HinfI (Fermentas) digestion by overnight 
incubation at 37 °C. Fragments were size-
separated by gel electrophoresis using 4 % 
(w/v) agarose. Allele C was not digested 
and remained 198 bp after digestion where-
as allele T was cut into two fragments of 
175 bp and 23 bp, thus heterozygous sub-
jects showed three fragments of 198, 175 
and 23 bp. 
 
Statistical analysis 
Continuous variables were presented as 
mean ± standard deviation (SD) and were 
compared by Student’s t-test or ANOVA 
for more than two groups. Scheffe's post-
hoc test was utilized to discriminate the 
significant differences among a group of 
means because it is fairly conservative and 
therefore very robust to the F-test outcome 
(Snedecor and Cochran, 1980). Kolmogo-
rov–Smirnov test was used to assess the 
normality of distribution of continuous var-
iables. Because of the right-skewed distri-
bution of tHcy and folate, analyses were 
performed using log-transformed data for 
these variables to reduce kurtosis. Thus ge-
ometric means of the mentioned variable 
are presented. Chi-square test was em-
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ployed to compare categorical variables as 
well as to assess the Hardy-Weinberg equi-
librium. We used univariate analyses to es-
timate the association of Hcy values with 
other variables. For this purpose, Pearson 
correlation coefficients were computed to 
evaluate the relationships between continu-
ous variables and Hcy concentrations 
whereas Student’s t-test was used to com-
pare the mean values of Hcy in dichoto-
mous variables (Hypertension, familial his-
tory of heart disease, smoking habit, diabe-
tes and sex). Subsequently, significantly as-
sociated variables were further analyzed by 
a multiple linear regression analysis to de-
termine independent predictors of plasma 
tHcy levels. A logistic regression model 
was fitted to examine the independent im-
pact of different clinical and biochemical 
factors on premature CAD. Furthermore, to 
evaluate the graded effect of Hcy concen-
trations on the risk of CAD, another logistic 
regression analysis - with Hcy quartiles as 
independent variables and the lowest quar-
tile as reference - was carried out. Respec-
tive odds ratios (OR) were calculated for an 
unadjusted analysis as well as for a adjusted 
model which had been controlled for pa-
rameters that may contribute to the risk for 
CAD such as MTHFR genotype, diabetes, 
sex, hypertension, age, lipid profile, famili-
al history and smoking status. Statistical 
analyses were all performed by the software 
package SPSS 17.0 (Statistical Package for 
the Social Science, SPSS, Inc., Chicago, Il-
linois) and a probability value ≤0.05 was 
used to establish statistical significance. 
 
RESULTS 
Clinical and biochemical parameters 
Baseline characteristics and clinical bio-
chemistry parameters of the patients and 
controls are summarized in Table 1. Alto-
gether 273 men (aged 21-50 years; mean 
47.44) and 258 women (aged 27-55 years; 
mean 51.13) were successfully genotyped 
in this study. As expected, the premature 
CAD group showed higher concentrations 
of LDL, triglyceride and Hcy, and lower 
concentrations of HDL compared with the 
control group. A significantly higher preva-
lence of diabetes, HHcy, familial history of 
heart disease and hypertension was also ob-
served in patients. Plasma folate concentra-
tion did not differ significantly between 
premature CADs and healthy subjects. The 
two groups were matched for age (P=0.439) 
and sex (p=0.088). The relative frequencies 
of males in the patient and control groups 
were 54.98 % and 48.67 % respectively. 
 
C677T polymorphism, premature CAD 
and homocysteine levels  
The prevalence of the MTHFR geno-
types was in the range of Hardy–Weinberg 
equilibrium both in the control (χ2=2.61, 
df=2, P=0.106) and patient (χ2=1.9, df=2, 
P=0.168) groups. C677T mutation frequen-
cy has been also presented in Table 1 for 
the patient and control groups. There was 
no significant difference between the two 
groups regarding genotype (χ2 = 2.874, df = 
2, P=238) and allele (χ2=3.132, df=1, 
P=082) frequencies. The TT genotype was 
observed in 8 % of the controls and 10.8 % 
of the patient group. No significant differ-
ence was observed in the prevalence of ei-
ther any genotype or allele frequencies be-
tween male and female subjects (P0.05).  
The premature CAD group consisted of 
231 patients (aged 29-55 years; mean 50.31 
years), including 78 (33.77 %) with one-, 
62 (26.84 %) with two-, and 91 (39.40 %) 
with three-vessel disease while no vessel 
disease group (aged 21-55 years; mean 
52.09 years) comprised of 300 subjects. 
Although a trend for higher prevalence of 
TT genotype was observed across the four 
subgroups of involved vessels, C677T poly-
morphism did not show a significant corre-
lation with the extent of premature CAD 
(P=0.641) (Table 2). On the other hand, as 
Table 2 displays, tHcy concentrations were 
significantly higher in patients with TVD 
(vs. SVD and NVD) and DVD (vs. NVD) 
(P<0.05 for both). In addition, the preva-
lence of HHcy was significantly lower in 
NVD subjects compared to DVD (P=0.027) 
and TVD (P=0.001) groups. Other investi-
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gated parameters had statistically similar 
distributions among different patient sub-
groups (i.e. SVD, DVD and TVD) (data not 
shown). Chi-square analysis also failed to 
find any significant difference in the num-
ber of diseased vessels between males and 
females (P0.05). 
Table 3 presents the distribution of bio-
chemical and clinical factors according to 
the MTHFR genotypes in the patient group. 
No significant association was observed be-
tween investigated factors and MTHFR 
genotypes except for the prevalence of 
HHcy and mean tHcy concentration. Pa-
tients with TT genotype had significantly 
higher concentrations of tHcy compared to 
the wild type homozygotes (P<0.001) and 
heterozygotes (P<0.05). A same trend was 
observed for HHcy (Table 3) as patients 
with thermolabile homozygous genotype 
(TT) were 1.894 times more likely to have 
HHcy than patients with C allele carriers 
(recessive genetic model: TT vs. CT+CC; 
OR=1.894, 95 % CI: 1.198-2.994, P=0.006). 
 
 
Table 1: Biological characteristics of participants in patient and control groups 
Variables Patients (SVD+DVD+TVD) (n=231) 
Controls 
(NVD) (n=300) P value 
Age (years) 50.31 ± 6.11 52.09 ± 7.03 0.439 
Gender (male/female) 127/104 146/154 0.088 
BMI (kg/m2) 25.74 ± 3.22 25.11 ± 3.87 0.542 
Total cholesterol (mg/dl) 159.26 ± 65.32 155.23 ± 67.28 0.382 
HDL cholesterol (mg/dl) 35.13 ± 8.43 38.16 ± 9.61 0.041 
LDL cholesterol (mg/dl) 117.71 ± 59.43 109.52 ± 57.39 0.014 
Triglycerides (mg/dl) 155.32 ± 63.21 140.25 ±61.65 0.039 
GM Folic acid (nmol/l) 9.87 ± 3.04 11.15 ± 3.21 0.433 
GM tHcy (μmol/l) 14.13 ± 4.11 10.19 ± 3.52 <0.001 
HHcy, n (%) 104 (45.02) 91 (30.33) 0.001 
Diabetes, n (%) 57 (24.67) 42 (14) 0.002 
Hypertension, n (%) 83 (35.93) 71 (23.67) 0.003 
Smokers, n (%) 65 (28.14) 77 (25.67) 0.554 
Familial history, n (%) 70 (30.30) 59 (19.67) 0.006 
MTHFR genotype, n (%) 
 CC 
 CT 
 TT 
 
118 (51.1) 
88 (38.1) 
25 (10.8) 
 
174 (58) 
102 (34) 
24 (8) 
 
 
 
0.238 
Alleles 
 C 
 T 
 
324 (70.13) 
138 (29.87) 
 
450 (75) 
150 (25) 
 
 
0.082 
Abbreviation: GM: Geometric Means; Continuous data are presented as mean ± SD 
 
Table 2: Distribution of MTHFR genotypes, HHcy and Hcy concentrations in studied population with 
different numbers of stenotic coronary artery 
 NVD (n=300) SVD (n=78) DVD (n=62) TVD (n=91) 
MTHFR genotypes 
 CC, n (%) 
 CT, n (%) 
 TT, n (%) 
 
174 (58) 
102 (34) 
24 (8) 
 
40 (51.28) 
31 (39.74) 
7 (8.97) 
 
34 (54.84) 
22 (35.48) 
6 (9.68) 
 
44 (48.35) 
35 (38.46) 
12 (13.19) 
GM tHcy (μmol/l) 10.19 ± 3.52 11.71 ± 2.87 13.12 ± 3.54† 14.54 ± 4.11* 
HHcy, n (%) 91 (30.33)‡ 31 (39.74) 28 (45.16) 45 (49.45) 
* Significantly different from NVD and SVD by ANOVA and Scheffe's post-hoc multiple comparison of the means of log-
transformed data (P<0.001) 
† Significantly different from NVD by ANOVA and Scheffe's post-hoc multiple comparison of the means of log-transformed da-
ta (P<0.01) 
‡ Significantly different from DVD (χ2=5.120, df=1, P=0.027) and TVD (χ2=11.249, df=1, P=0.001) 
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Table 3: Biochemical and clinical parameters in premature CAD subjects (SVD+DVD+TVD) with  
different MTHFR genotypes 
Variables 677CC (n=118) 677CT (n=88) 677TT (n=25) 
Age (years) 50.24 ± 6.07 49.32 ± 6.01 51.43 ± 7.13  
BMI (kg/m2) 24.89 ± 3.92 25.53 ± 3.60 26.11 ± 3.86 
Total cholesterol (mg/dl) 156.43 ± 59.11 158.73 ± 62.02 160.03 ± 66.04 
HDL cholesterol (mg/dl) 36.44 ± 9.12 37.53 ± 8.76 34.82 ± 8.28 
LDL cholesterol (mg/dl) 114.83 ± 54.82 120.47 ± 61.60 117.33 ± 57.64 
Triglycerides (mg/dl) 153.75 ± 59.73 154.76 ± 57.33 156.86 ± 62.22 
GM Folic acid (nmol/l) 10.88 ± 4.05 9.66 ± 3.67 9.34 ± 3.11 
GM tHcy (μmol/l) 11.56 ± 3.89 13.89 ±3.83 15.82 ± 4.05*† 
HHcy, n (%) 46 (39.98) 40 (45.45) 18 (72)‡ 
Diabetes, n (%) 31 (26.27) 20 (22.73) 6 (24) 
Hypertension, n (%) 41 (34.75) 34 (38.64) 8 (32) 
Smokers, n (%) 33 (27.97) 25 (28.41) 7 (28) 
Familial history, n (%) 35 (29.66) 29 (32.95) 6 (24) 
† Significantly different from CC by ANOVA and Scheffe's post-hoc multiple comparison of the means of log-
transformed data (P<0.001) 
* Significantly different from CT by ANOVA and Scheffe's post-hoc multiple comparison of the means of log-
transformed data (P<0.05) 
‡ Significantly different from CC (χ2=9.095, df=1, P=0.004) and CT (χ2=5.491, df=1, P=0.024) 
 
 
Determinants of tHcy concentrations 
In univariate analysis plasma tHcy lev-
els were correlated with folate level  
(r=-0.183, P=0.002). Likewise, the mean 
tHcy level was found to be higher in smok-
ers and those with thermolabile homozy-
gous genotype (recessive model; TT vs. 
CC+CT). Finally, the stepwise multiple lin-
ear regression analysis which was adjusted 
for folate and smoking status (adjusted 
R2=0.38, P<0.001), showed that rs1801133 
in the recessive model was a significantly 
independent predictor of tHcy levels 
(P < 0.001; Table 4). 
 
Predictors of premature coronary artery 
disease 
In order to identify effective factors 
predisposing to premature CAD, a logistic 
regression analysis with backward selection 
strategy was conducted. Categorical varia-
bles (hypertension, gender, diabetes, 
MTHFR genotypes, familial history of 
heart disease and tobacco use) and continu-
ous factors (tHcy, folate, TC, TG, HDL, 
LDL, BMI and age) were included in the 
model as independent variables. Results 
showed an independent association between 
tHcy and the risk of premature CAD 
(OR=9.04, 95% CI: 2.64-26.11; P =0.001). 
Hypertension, diabetes, familial history of 
heart disease and LDL cholesterol were al-
so independently associated with premature 
CAD (Table 5). 
Additionally, to evaluate the graded im-
pact of tHcy levels on the premature CAD, 
a logistic regression analysis was performed 
with the independent variable being Hcy 
quartiles. In our population 25th, 50th and 
75th percentiles of Hcy (ranged from 
min=3.50 to max=69 μmol/l) were 9.92, 
13.19 and 17.02 μmol/l respectively. Table 
6 presents association results between ho-
mocysteine quartiles and risk of premature 
CAD in two models: unadjusted model and 
a model adjusted for conventional risk fac-
tors of coronary atherosclerotic disease 
such as smoking, hypertension, lipids, age, 
diabetes, positive familial history of heart 
disease, MTHFR and sex. Apparently the 
odds ratio (OR) for premature CAD in-
creased with increasing quartiles of Hcy 
(Ref=lowest quartile) both before and after 
adjustment. The adjusted model showed 
that subjects in the top two homocysteine 
quartiles (≥17.03 and 13.20-17.02 μmol/l) 
are 2.04 (95 % CI, 1.65-3.07) and 2.13 
(95 % CI, 1.81-3.13) times more likely to 
have premature CAD than those in the first 
quartile (≤9.92 μmol/L) (P<0.001 for both) 
(Table 6).  
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Table 4: Multivariate regression analysis for tHcy levels 
 
Univariate analysis Multivariate analysis 
R* P value β P value 
rs1801133, TT vs. CC+CT - <0.001 0.221 <0.001 
Folate  -0.183 0.002 0.192 0.011 
Smokers - 0.012 0.093 0.038 
Diabetes - 0.123   
Familial history - 0.168   
Sex  - 0.766   
Age  0.067 0.284   
BMI  0.046 0.342   
Total cholesterol  0.022 0.643   
HDL cholesterol  0.112 0.085   
LDL cholesterol  0.073 0.114   
Triglycerides  0.033 0.532   
*Calculated for log-transformed data of tHcy 
 
Table 5: Risk factors for premature CAD with logistic regression 
Risk factors β-coefficient Standard error Adjusted OR (95 % CI) P value 
tHcy 2.011 0.916 9.04 (2.64-26.11) 0.001 
Hypertension 0.885 0.332 2.31 (1.39-3.77) 0.011 
Diabetes 0.753 0.265 2.09 (1.17-3.43) 0.026 
Familial history 0.722 0.301 2.21 (1.24-3.69) 0.033 
LDL cholesterol 0.901 0.442 2.29 (1.32-3.87) 0.020 
 
Table 6: Association between tHcy quartiles and risk of premature CAD 
tHcy quartile 
(μmol/l) 
OR 
(unadjusted) 
OR 
(adjusted) 
≤ 9.92 (reference) - - 
9.93-13.19 1.32 (0.72-2.33) 1.19 (0.67-2.09) 
13.20-17.02 3.44 (1.87-7.02)* 2.04 (1.65-3.07)*
≥ 17.03 5.11 (2.97-10.02)* 2.13 (1.81-3.13)*
*P < 0.001 compared with the reference group (first quartile) 
 
 
DISCUSSION 
Homocysteine hypothesis indicates that 
mild to moderate hyperhomocysteinemia is 
an independent predictor for the develop-
ment of cardiovascular disease (CVD). 
However, there are also studies which have 
shed doubt on the role of this thiol-
containing amino acid in the pathogenesis 
of atherosclerotic vascular disease (re-
viewed in Ueland et al., 2000; Lentz and 
Haynes, 2004). These controversial results 
brought up a homocysteine controversy in-
stead of the homocysteine hypothesis (re-
viewed in Smulders and Blom, 2011). In 
addition, several numbers of studies, from 
the early 1990s, have introduced various 
evidences for the genetic basis of elevated 
levels of Hcy (reviewed in Trabetti, 2008). 
Among the candidate genes, the MTHFR is 
of particular medical interest as being a risk 
factor for hyperhomocysteinemia as well as 
for CVD. Although some meta-analyses 
have found an association between the 
MTHFR 677T allele and atherosclerosis, 
vascular disease and myocardial infarction 
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(Wald et al., 2002; Cronin et al., 2005; 
Laraqui et al., 2007), others failed to detect 
such a relationship (Brattstrom et al., 1998; 
Klerk et al., 2002). Ethnicity differences 
could be a responsible parameter for at least 
some of these controversial results.  
The result of this investigation did not 
support an independent association of the 
MTHFR C677T polymorphism either with 
the presence of premature CAD or with its 
extent. However, a positive relationship 
was observed between the TT MTHFR 
genotype and elevated plasma tHcy levels. 
Folic acid and smoking habits were also 
among the significant predictors of tHcy 
levels in the current study. Folate status is 
the most important determinant of plasma 
homocysteine levels in the general popula-
tion (Nygard et al., 1998; Selhub et al., 
1999), and its low intake or blood concen-
trations increase the risk of CVD (Morrison 
et al., 1996; Rimm et al., 1998). Several 
mechanisms such as lipid peroxidation, 
platelet activation and aggregation, reduced 
VonWillebrand factor, inflammation, hy-
pertension, endothelial damage and vaso-
constriction (Harker et al., 1976; Fryer et 
al., 1993; Bartecchi et al., 1994; MacKenzie 
et al., 1994) have been suggested to explain 
the causal role of smoking on coronary ath-
erosclerosis so far. Due to these results, the 
presence of a direct and consistent associa-
tion between the gene variant and plasma 
tHcy levels is admitted in the studied popu-
lation. 
On the other hand, in the current study 
tHcy level was positively associated not on-
ly with the presence of premature CAD but 
also with the number of involved vessels 
which is in agreement with some previous 
reports regarding the correlation between 
tHcy levels and number of atherosclerotic 
vessels (von Eckardstein et al., 1994; Mon-
talescot et al., 1997; Chao et al., 1999; Tok-
gozoglu et al., 1999; Yoo et al., 1999; Ker-
keni et al., 2006; Alam et al., 2008). There 
are also a few case-control studies in the 
literature which were unable to verify such 
a relationship (Bozkurt et al., 2003; Guer-
zoni et al., 2009). There is still a study in 
which tHcy levels showed a significant cor-
relation with the extent of coronary athero-
sclerosis in patients with low cardiovascular 
risk profiles unlike in patients with high 
risk profiles (Tsai et al., 2000). These con-
troversial results involving the relation be-
tween plasma tHcy levels and the extent of 
CAD could be partly attributed to the varia-
ble stenosis criteria used in defining CAD 
by different studies. Some investigators 
have considered ≥ 50 % stenosis as the cut 
off point for CAD diagnosis (von Eckard-
stein et al., 1994; Tokgozoglu et al., 1999; 
Kerkeni et al., 2006; Guerzoni et al., 2009), 
whereas in other studies CAD criterion has 
been taken to be ≥ 70-75 % stenosis 
(Montalescot et al., 1997; Chao et al., 1999; 
Yoo et al. 1999; Alam et al., 2008). Moreo-
ver homocysteine circulating levels are af-
fected by some various factors that differ in 
each population such as genetic factors, die-
tary habits, geographic and demographic 
differences and life style (Bayer et al., 
2002; Bozkurt et al., 2003). Additionally 
independent risk factors predisposing indi-
viduals to atherosclerosis may also vary 
among various populations.  
Furthermore, like some previous reports 
(Verhoef et al., 1997; Chao et al., 1999; 
Selhub et al., 2000; Pajunen et al., 2002; 
Panayiotou et al., 2009) we found evidence 
of a graded effect of Hcy quartiles on the 
risk of premature CAD. Significant odds ra-
tios of top two Hcy quartiles in comparison 
to the lowest quartile even after controlling 
for other conventional risk factors of CVD 
together with the robust association of tHcy 
levels with TT genotypes of MTHFR gene 
makes it reasonable to suggest that MTHFR 
mutation mediates its influence on athero-
sclerosis by means of HHcy. 
In conclusion, these data suggest that an 
elevated plasma Hcy level, but not MTHFR 
mutation, is associated with the extent of 
premature coronary artery disease. In addi-
tion, our findings admit the role of the 
MTHFR T allele as an independent deter-
minant of plasma tHcy concentration. 
However, the present study has some limi-
tations. Pathologic studies have shown that 
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arterial thrombosis and plaque rupture are 
episodic events which could significantly 
affect the severity of stenosis at the time of 
angiography (Sullivan et al., 1990). On the 
other hand, it has been revealed that more 
than 50 % of the coronary surface is usually 
covered by raised plaque (Solberg and 
Strong, 1983) and considerable portion of 
coronary events could be resulted from 
their progression (Azen et al., 1996). Thus, 
estimating the extent of CAD by the num-
ber of involved vessels would contribute to 
underestimate the risk of atherosclerosis 
and may not provide the best reflection of 
this process. There are multiple scoring sys-
tems (Leaman et al., 1981; Gensini, 1983; 
Sullivan et al., 1990; Montalescot et al., 
1994; Birnie et al., 1998) which can evalu-
ate the severity or extent of CAD much bet-
ter than traditional vessel score approach 
used here. Besides, some other key deter-
minants of plasma tHcy levels such as vit-
amins B6 and B12, caffeine consumption, 
creatinine concentration and exercise were 
not taken into account in the present inves-
tigation. Since TT genotype, smoking status 
and folic acid levels can only predict 38 % 
of tHcy changes in our population (Table 
4), assessment of other Hcy predictors seem 
indispensible. 
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